Brief: HanAll Biopharma Invests In Interon To Seek Collaboration Opportunities
10/02/2023 12:50
Feb 10 (Reuters) - Hanall Biopharma Co Ltd 009420.KS :
* HANALL BIOPHARMA INVESTS IN INTERON TO SEEK COLLABORATION
OPPORTUNITIES
* HANALL BIOPHARMA CO- INVESTMENT TO FUND INTERON'S
CONTINUED
DEVELOPMENT OF ITS LEAD PROGRAMS TARGETING AN ARRAY OF
NEUROLOGICAL AND IMMUNE DISORDERS
Source text for Eikon: ID:nPnSQH7ka
Further company coverage: 009420.KS
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies